Cargando…
RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse progn...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164706/ http://dx.doi.org/10.1093/neuonc/noac079.044 |
_version_ | 1784720199358873600 |
---|---|
author | Petropoulos, James Finkbeiner, Melanie Assis, Zarina Gallagher, Clare Hader, Walter Chan, Jennifer Strother, Douglas Lafay-Cousin, Lucie |
author_facet | Petropoulos, James Finkbeiner, Melanie Assis, Zarina Gallagher, Clare Hader, Walter Chan, Jennifer Strother, Douglas Lafay-Cousin, Lucie |
author_sort | Petropoulos, James |
collection | PubMed |
description | INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse prognostic factor. We present 2 cases of young children with recurrent metastatic DIA/DIG to describe their presentation, therapeutic management and outcome and to highlight the importance of molecular characterization of these rare tumors to guide adjuvant therapy. CASES DESCRIPTION: The first patient developed metastatic recurrence after initial gross total resection (GTR) of a localized DIG. The disseminated relapse was treated with monthly carboplatin and vincristine (CB/VCR). Complete response was achieved after 15 cycles and the patient has remained in continuous complete remission for 5 years. Post hoc molecular analysis of the tumor revealed a BRAF-RDX fusion. The second patient presented with a disseminated intraventricular relapse following an incomplete resection of a DIA associated with a SPECC1L-NTRK2 fusion. The patient received 2 cycles of CB/VCR with minimal response and was then switched to Larotrectinib leading to a very good partial response (VGPR) 3 months into therapy and has remained on treatment since then with significant clinical improvement. DISCUSSION/ CONCLUSION: In our 2 cases, metastatic recurrence was responsive to adjuvant therapy leading to complete response with conventional chemotherapy in the first one and to VGPR with NTRK inhibitor in the second patient. Early molecular characterization of these benign tumors is critical in case of incomplete resection or metastatic seeding to widen therapeutic options and maximize chance of cure. Response with NTRK inhibitor appears rapid and significant but the total duration of treatment and sustainability of response after discontinuation remain unknown. |
format | Online Article Text |
id | pubmed-9164706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91647062022-06-05 RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG Petropoulos, James Finkbeiner, Melanie Assis, Zarina Gallagher, Clare Hader, Walter Chan, Jennifer Strother, Douglas Lafay-Cousin, Lucie Neuro Oncol Craniopharyngioma and Rare Tumors INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse prognostic factor. We present 2 cases of young children with recurrent metastatic DIA/DIG to describe their presentation, therapeutic management and outcome and to highlight the importance of molecular characterization of these rare tumors to guide adjuvant therapy. CASES DESCRIPTION: The first patient developed metastatic recurrence after initial gross total resection (GTR) of a localized DIG. The disseminated relapse was treated with monthly carboplatin and vincristine (CB/VCR). Complete response was achieved after 15 cycles and the patient has remained in continuous complete remission for 5 years. Post hoc molecular analysis of the tumor revealed a BRAF-RDX fusion. The second patient presented with a disseminated intraventricular relapse following an incomplete resection of a DIA associated with a SPECC1L-NTRK2 fusion. The patient received 2 cycles of CB/VCR with minimal response and was then switched to Larotrectinib leading to a very good partial response (VGPR) 3 months into therapy and has remained on treatment since then with significant clinical improvement. DISCUSSION/ CONCLUSION: In our 2 cases, metastatic recurrence was responsive to adjuvant therapy leading to complete response with conventional chemotherapy in the first one and to VGPR with NTRK inhibitor in the second patient. Early molecular characterization of these benign tumors is critical in case of incomplete resection or metastatic seeding to widen therapeutic options and maximize chance of cure. Response with NTRK inhibitor appears rapid and significant but the total duration of treatment and sustainability of response after discontinuation remain unknown. Oxford University Press 2022-06-03 /pmc/articles/PMC9164706/ http://dx.doi.org/10.1093/neuonc/noac079.044 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Craniopharyngioma and Rare Tumors Petropoulos, James Finkbeiner, Melanie Assis, Zarina Gallagher, Clare Hader, Walter Chan, Jennifer Strother, Douglas Lafay-Cousin, Lucie RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title | RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title_full | RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title_fullStr | RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title_full_unstemmed | RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title_short | RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG |
title_sort | rare-19. molecular characterization and treatment response of metastatic dia/dig |
topic | Craniopharyngioma and Rare Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164706/ http://dx.doi.org/10.1093/neuonc/noac079.044 |
work_keys_str_mv | AT petropoulosjames rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT finkbeinermelanie rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT assiszarina rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT gallagherclare rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT haderwalter rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT chanjennifer rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT strotherdouglas rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig AT lafaycousinlucie rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig |